BELLUS Health Convenes KOL Meeting to Discuss the State of Chronic Cough Treatment
July 15 2019 - 7:00AM
Business Wire
- Professor Jacky Smith from the University of
Manchester to lead live webcast -
BELLUS Health Inc. (TSX: BLU) ("BELLUS Health" or the
"Company"), a clinical-stage biopharmaceutical company developing
novel therapeutics for the treatment of chronic cough and other
hypersensitization-related disorders, today announced that it will
convene a Key Opinion Leader meeting to discuss chronic cough on
Tuesday, July 16, 2019 in New York City. The event will include
discussions on the unmet medical need in the category, and a review
of current therapies in development including P2X3 antagonists.
BELLUS Health will also provide clinical and regulatory updates on
its lead P2X3 antagonist product candidate for the treatment of
chronic cough, BLU-5937.
Dr. Jacky Smith, MB, ChB, FRCP, PhD, is a Professor of
Respiratory Medicine at the University of Manchester, UK and an
Honorary Consultant at University Hospital of South Manchester NHS
Foundation Trust. She runs a multi-disciplinary research team whose
focus is on understanding mechanisms underlying pathological cough,
and a regional clinical service seeing patients with refractory
chronic cough. Her main research interests lie in developing new
endpoints in cough monitoring, understanding the mechanisms
underlying cough in respiratory diseases and the testing of novel
anti-tussive therapies. She is the Principal Investigator of BELLUS
Health’s Phase 2 study of BLU-5937 in refractory chronic cough.
Meeting Details:
Event: BELLUS Health Chronic Cough KOL Meeting
Date: Tuesday, July 16, 2019 Time: 8:30 a.m.-11:30
a.m. EDT
The live webcast of the event may be accessed through the Events
and Presentations page of BELLUS Health’s website, under the
Investors & News section. The archived webcast and presentation
will be available on the Company’s website after the event.
About BELLUS Health (www.bellushealth.com)
BELLUS Health is a clinical-stage biopharmaceutical company
developing novel therapeutics for the treatment of chronic cough
and other hypersensitization-related disorders. The Company's lead
product candidate, BLU-5937, is being developed for the treatment
of chronic cough. BLU-5937, a highly selective P2X3 antagonist, has
the potential to be a best-in-class therapeutic for chronic cough
patients who do not respond to current therapies. In addition to
chronic cough, BLU-5937 may potentially have clinical benefit in
other afferent hypersensitization-related disorders, such as
visceral pain, hypertension, and migraine, among others. BELLUS
Health is currently conducting preclinical studies in additional
undisclosed indications.
Chronic cough is classified as a cough lasting more than eight
weeks and is associated with significant adverse social,
psychosocial and physical effects on health and quality-of-life.
More than 26 million adults in the United States suffer from
chronic cough. Of these patients, more than 2.6 million have
unexplained or refractory chronic cough lasting for more than a
year. There are currently no approved therapeutics for the
treatment of chronic cough.
Forward-Looking Statements
Certain statements contained in this news release, other than
statements of fact that are independently verifiable at the date
hereof, may constitute “forward-looking statements” within the
meaning of Canadian securities legislation and regulations. Such
statements, based as they are on the current expectations of
management, inherently involve numerous important risks,
uncertainties and assumptions, known and unknown, many of which are
beyond BELLUS Health Inc.'s control. Such risks factors include but
are not limited to: the ability to expand and develop its project
pipeline, the ability to obtain financing, the impact of general
economic conditions, general conditions in the pharmaceutical
industry, changes in the regulatory environment in the
jurisdictions in which BELLUS Health Inc. does business, stock
market volatility, fluctuations in costs, changes to the
competitive environment due to consolidation, achievement of
forecasted burn rate, potential payments/outcomes in relation to
indemnity agreements and contingent value rights, achievement of
forecasted pre-clinical and clinical trial milestones and that
actual results may vary once the final and quality-controlled
verification of data and analyses has been completed. In addition,
the length of BELLUS Health Inc.’s product candidates’ development
process, their market size and commercial value, as well as the
sharing of proceeds between BELLUS Health Inc. and its potential
partners from potential future revenues, if any, are dependent upon
a number of factors. Consequently, actual future results and events
may differ materially from the anticipated results and events
expressed in the forward-looking statements. BELLUS Health Inc.
believes that expectations represented by forward-looking
statements are reasonable, yet there can be no assurance that such
expectations will prove to be correct. The reader should not place
undue reliance, if any, on any forward-looking statements included
in this news release. These forward-looking statements speak only
as of the date made, and BELLUS Health Inc. is under no obligation
and disavows any intention to update publicly or revise such
statements as a result of any new information, future event,
circumstances or otherwise, unless required by applicable
legislation or regulation. Please see BELLUS Health Inc.’s public
filings with the Canadian securities regulatory authorities,
including the Annual Information Form, for further risk factors
that might affect BELLUS Health Inc. and its business.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20190715005177/en/
Investors: Solebury Trout Chad
Rubin 646-378-2947 crubin@troutgroup.com Media: Solebury Trout Joshua R Mansbach
646-378-2964 jmansbach@troutgroup.com
BELLUS Health (TSX:BLU)
Historical Stock Chart
From Mar 2024 to Apr 2024
BELLUS Health (TSX:BLU)
Historical Stock Chart
From Apr 2023 to Apr 2024